Mikhail Blagosklonny is the appropriate scientist to be consulted in a field that requires one to study and understand cancer and aging. The former professor of Oncology at New York’s Roswell Park Cancer Institute has managed to train several oncologists. Mikhail earned is Doctor of Medicine Degree in Internal Medicine at the First Pavlov State Medical University of St. Petersburg. He later received his Ph.D. in Experimental Medicine and Cardiology from the same University. Mikhail was an associate professor of Medicine at New York Medical College for seven years before he was appointed as Oncology, a professor at Roswell Park Cancer Institute. He has done several types of research on cancer and its therapies that do not damage healthy cells. Mikhail has also done research on aging and anti-aging drugs. Read more on templeofthecave.com
Use of Rapamycin in the treatment of cancer and aging
In a paper that was published by Impact Journal, Mikhail says that aging is not a disease and trying to cure it is misguided and not scientific. In this paper, aging is described as a continuous growth that is enhanced by signaling pathways such as TOR. The TOR centric model has got three sources namely; genetic longevity, cellular senescence, and diseases. It was also predicted that Rapamycin could be used to treat aging and diseases related to it. The prediction was made in 2008 and was taken for granted by opponents as it was not viable to them. Eight years later, it is becoming a turning point in scientific research.
In 2006, rapamycin was approved for use clinically. It was immediately administered to treat diseases like autoimmunity, metabolic disorders, cardiovascular disorders, and cancer. The drug can be administered to patients for an extended period without adverse side effects. It rejuvenates the patients’ immunity, unlike other drugs that suppress the immunity. The drug can be administered orally and on a daily basis. It is safe and not toxic to the body cells.
Prof. Mikhail Blagosklonny is currently working as the editor-in-chief of Oncotarget and Cell Cycle. He serves on the editorial board that deals with cell death and differentiation. His research covers several areas of cellular and molecular biology and clinical trials. In his research, Mikhail focuses on transduction, cell apoptosis, tumor suppression, and cell cycle. He also deals with drug resistance for cells that are healthy, mitosis and anticancer therapeutics. He has more than 300 articles that give insight on cancer cure and anti-aging drugs. Mikhail is among one of the most know rapamycin advocates. His day to day research work is driven by his desire to see a disease free world. The professor is a scientific researcher who has put a lot of dedication into his work making one of the best oncologists globally.